Details for Patent: 10,328,029
Which drugs does patent 10,328,029 protect, and when does it expire?
Patent 10,328,029 protects NITYR and is included in one NDA.
This patent has fifteen patent family members in fifteen countries.
Summary for Patent: 10,328,029
| Title: | Pharmaceutical composition |
| Abstract: | The present invention relates to oral pharmaceutical compositions comprising nitisinone, or a pharmaceutically acceptable salt thereof, their use in the treatment of tyrosinemia, such as Hereditary Tyrosinemia type-1 (HT-1), or alkaptonuria. The compositions have improved stability characteristics. The invention also relates to processes for producing nitisinone. |
| Inventor(s): | James Harrison, Stephen Fuller, Tobias Josef Brown |
| Assignee: | Cycle Pharmaceuticals Ltd |
| Application Number: | US15/109,220 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; |
Drugs Protected by US Patent 10,328,029
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle | NITYR | nitisinone | TABLET;ORAL | 209449-001 | Jul 26, 2017 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | TREATMENT OF HEREDITARY TYROSINEMIA TYPE 1 (HT-1) IN COMBINATION WITH DIETARY RESTRICTION OF TYROSINE AND PHENYLALANINE | ⤷ Start Trial | |||
| Cycle | NITYR | nitisinone | TABLET;ORAL | 209449-002 | Jul 26, 2017 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | TREATMENT OF HEREDITARY TYROSINEMIA TYPE 1 (HT-1) IN COMBINATION WITH DIETARY RESTRICTION OF TYROSINE AND PHENYLALANINE | ⤷ Start Trial | |||
| Cycle | NITYR | nitisinone | TABLET;ORAL | 209449-003 | Jul 26, 2017 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | TREATMENT OF HEREDITARY TYROSINEMIA TYPE 1 (HT-1) IN COMBINATION WITH DIETARY RESTRICTION OF TYROSINE AND PHENYLALANINE | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 10,328,029
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| United Kingdom | 1400117.6 | Jan 3, 2014 |
| PCT Information | |||
| PCT Filed | January 05, 2015 | PCT Application Number: | PCT/GB2015/050006 |
| PCT Publication Date: | July 09, 2015 | PCT Publication Number: | WO2015/101794 |
International Family Members for US Patent 10,328,029
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Canada | 2935013 | ⤷ Start Trial | |||
| Cyprus | 1123394 | ⤷ Start Trial | |||
| Denmark | 3089740 | ⤷ Start Trial | |||
| European Patent Office | 3089740 | ⤷ Start Trial | |||
| Spain | 2806739 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
